Tachyon Therapeutics Stock

Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer.

Sign up today and learn more about Tachyon Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Tachyon Therapeutics Stock

Tachyon Therapeutics develops novel, selective compounds to improve the treatment of cancer. The company is currently conducting Phase 1 clinical research in patients with advanced cancer to assess the safety, pharmacokinetics, and anti-tumor effectiveness of TACH101. The programs will be advanced in a timely, innovative, high-quality, and scientifically sound manner.

Funding History

March 2023$7.1M
March 2023$11.6M

Management

Chief Executive Officer

Frank Perabo

Board Member

Jeffrey Stafford

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo